Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Off-Label Cancer Drug Policy Will Have "Very Narrow" Focus

This article was originally published in The Pink Sheet Daily

Executive Summary

Policy decision for covering unapproved, non-compendial indications for cancer drugs is still pending, but will not mean a "sea change" in reimbursement, agency official says. Real issue is "unorganized" approach to off-label use as a whole in the U.S.
Advertisement

Related Content

Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen and Thalidomide
Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen and Thalidomide
NCI/CMS Group Will Examine Coverage For Off-Label Cancer Drug Use
NCI/CMS Group Will Examine Coverage For Off-Label Cancer Drug Use
Thalidomide Off-Label Coverage
Thalidomide Off-Label Coverage
Off-Label Drug Use To Receive CMS Scrutiny, McClellan Says
Off-Label Drug Use To Receive CMS Scrutiny, McClellan Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS059363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel